Grace Therapeutics (GRCE) Cash from Financing Activities (2019 - 2025)

Grace Therapeutics (GRCE) posted Cash from Financing Activities of $4.0 million for Q4 2025, up 1335.47% sequentially from -$327000.0 in Q2 2025.

Grace Therapeutics (GRCE) Cash from Financing Activities (2019 - 2025) Analysis & Trends

Grace Therapeutics has reported Cash from Financing Activities for 6 years, with the latest figure at $4.0 million in Q4 2025.

Quarterly Cash from Financing Activities changed N/A year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 73.54% YoY) and the FY2026 annual result came in at $3.7 million, down 73.54% from the prior year.
Cash from Financing Activities rose to $4.0 million in Q4 2025 per GRCE's latest filing, from -$327000.0 in the prior quarter.
Over five years, Cash from Financing Activities peaked at $34.7 million in Q1 2021 and troughed at -$327000.0 in Q2 2025.
A 4-year average of $8.6 million and a median of $4.0 million in 2025 frame the typical range for Cash from Financing Activities.
The sharpest annual moves came in 2021 and 2023: Cash from Financing Activities jumped 163.19% in 2021, then jumped 6651.38% in 2023.
Over 4 years, Cash from Financing Activities stood at $34.7 million in 2021, then sank by 99.69% to $109000.0 in 2022, then surged by 6651.38% to $7.4 million in 2023, then sank by 45.1% to $4.0 million in 2025.
According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.0 million, -$327000.0, and $14.0 million for Q4 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-426.70 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-1.22 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	14.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-6.05 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	36.24 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	27.18 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-273.15 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.65 Mn
10	Grace Therapeutics	37.04 Mn	37.04 Mn	-	-

Download Data